The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1378-1381 , December 2007

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

Received 8 August 2007 ,Revised 17 September 2007 ,Accepted 18 September 2007.

References 

  1. Genentech Inc. Xolair (omalizumab): full prescribing information. 2007. Available at: http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf. Accessed September 24, 2007.
  2. Omalizumab: healthcare professional sheet. US Food and Drug Administration. 2007. Available at: http://www.fda.gov/cder/drug/infopage/omalizumab/default.htm. Accessed August 6, 2007.
  3. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28:313–319
  4. Chipps B. Systemic reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;97:267
  5. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96:624–627
  6. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391–397
  7. Inomata N, Osuna H, Yanagimachi M, Izekawa Z. Late-onset anaphylaxis to fermented soybeans: the first confirmation of food-induced, late-onset anaphylaxis by provocation test. Ann Allergy Asthma Immunol. 2005;94:402–406
  8. Green TD, Palmer KP, Burks AW. Delayed anaphylaxis to walnut following epinephrine administration. J Pediatr. 2006;149:733–734
  9. Shibasaki M, Ehara T, Takita H. Late anaphylactic reaction to cuttlefish. Ann Allergy. 1989;63:421–422
  10. Ghaffari G, Craig T, Golden DF, Chegini S. Delayed and recurrent anaphylaxis reaction to yellow jacket sting. J Allergy Clin Immunol. 2006;117(suppl 1):S309
  11. Oyefara BI, Bahna SL. Delayed food-dependent, exercise-induced anaphylaxis. Allergy Asthma Proc. 2007;28:64–66
  12. Matloff SM, Bailit JW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14:347–350
  13. Greenberg MA, Kaufman CR, Gonzalez GE, Trusewych ZP, Rosenblatt CD, Summers RJ. Late systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol. 1988;82:287–290
  14. Bousquet PJ, Kvedariene V, Co-Minh HB, Martins P, Rongier M, Arnouz B, et al. Clinical presentation and time course in hypersensitivity reactions to beta-lactams. Allergy. 2007;62:872–876
  15. Spiegel RJ, Echelberger CK, Poplack DG. Delayed allergic reactions following intramuscular L-asparaginase. Med Pediatr Oncol. 1980;8:123–125
  16. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250–256
  17. Genentech Inc. Herceptin (trastuzumab): full prescribing information. 2000. Available at: http://www.gene.com./gene/products/information/pdf/herceptin-prescribing.pdf. Accessed September 24, 2007.
  18. Roche Pharmaceuticals. Zenapax (daclizumab): full prescribing information. 2005. Available at: http://www.rocheusa.com/products/zenapax/pi.pdf. Accessed September 24, 2007.
  19. Novartis Pharmaceutical Corp. Simulect (basiliximab): full prescribing information. 2005. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf. Accessed September 24, 2007.
  20. Wyeth Pharmaceuticals Inc. Mylotarg (gemtuzumab ozogamicin for injection): full prescribing information. 2007. Available at: http://www.wyeth.com/content/ShowLabeling.asp?id=119. Accessed on September 24, 2007.
  21. Brady WJ, Luber S, Carter CT, Guertler A, Lindbeck G. Multiphasic anaphylaxis: an uncommon event in the emergency department. Acad Emerg Med. 1997;4:193–197
  22. Brown AG, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol. 2001;108:861–866
  23. Briefing document on safety, BLA STN 103976/0. US Food and Drug Administration. April 18, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3952B1_02_FDA-Xolair-Safety.pdf. Accessed August 30, 2007.

 Disclosure of potential conflict of interest: The authors are employed by the US Food and Drug Administration.

 The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of the US Food and Drug Administration.

PII: S0091-6749(07)01781-2

doi: 10.1016/j.jaci.2007.09.022

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1378-1381 , December 2007

Article Tools